AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesDisciplines and OccupationsAnthropology, Education, Sociology and Social PhenomenaTechnology, Industry, AgricultureInformation ScienceNamed GroupsHealth CareGeographicals
GlucagonDiabetes Mellitus, Type 1Diabetes MellitusReceptors, GlucagonDiabetes Mellitus, Type 2Diabetes ComplicationsDiabetes Mellitus, ExperimentalInsulinBlood GlucoseGlucagon-Secreting CellsDiabetes, GestationalIslets of LangerhansHypoglycemic AgentsHemoglobin A, GlycosylatedTherapeuticsHypoglycemiaLiverGlucoseHyperglycemiaDiabetes InsipidusPancreasSomatostatinRisk FactorsGlucose Tolerance TestGlucagon-Like Peptide 1Pharmacy and Therapeutics CommitteeGluconeogenesisInsulin-Secreting CellsFastingProglucagonC-PeptideGlucagon-Like PeptidesStreptozocinPancreatic HormonesInsulin ResistanceObesityPancreatic PolypeptideTime FactorsPrediabetic StateDiabetic NephropathiesRats, Inbred StrainsMice, Inbred NODPharmacology, ClinicalEpinephrineDrug Delivery SystemsDiabetic RetinopathyNeoplasmsDiabetic NeuropathiesGlucose IntoleranceDisease Models, AnimalLiver GlycogenMetforminBlood Glucose Self-MonitoringPregnancy in DiabeticsCyclic AMPPrevalenceRats, Inbred BBBody Mass IndexDrug DesignReceptors, Gastrointestinal HormoneCardiovascular DiseasesDogsCohort StudiesAdenylate CyclaseDose-Response Relationship, DrugDiabetic KetoacidosisGlucose Clamp TechniqueCells, CulturedSelf CareFatty Acids, NonesterifiedPeptidesHormonesKineticsSulfonylurea CompoundsProspective StudiesMolecular Targeted TherapyCross-Sectional StudiesBiological MarkersAlbuminuriaGastric Inhibitory PolypeptideUnited StatesFollow-Up StudiesReference ValuesDiabetic DietCase-Control StudiesIncidenceHypertensionBody WeightTreatment OutcomeArginineHomeostasisPostprandial PeriodVenomsGenetic Predisposition to DiseaseAntineoplastic AgentsSecretinLipidsDrug Evaluation, PreclinicalDrug Discovery3-Hydroxybutyric Acid
AgonistSecretionAgonistsIncretinMellitusBlood glucoseProduction of glucagonTherapeuticInhibits glucagonGastricPharmacologySemaglutideHormoneClinicalStructure TherapeuticsExenatideCardiovascularPeptidesTherapiesT2DMAntagonistExocrine pancreasPancreasNASDAQ2016LiraglutideAnalogsHuman isletsPrevalence of type 2 diabetPathwaysTranslationalPotentIsletsMetabolic disorderGlycemic controlPeople with type 2 diabetTreatment of type 2 diabetSuppressionHomeostasisGestationalType 2 diabetes and obesiRegulatesVitroTreat type 2 diabetGlucose controlInternational Diabetes FConcentrationsPancreatic cellsNewly diagnosedLillyObeseSystemicProteinPatients
Agonist26
  • The injectable glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Wegovy), which was approved by the FDA in 2021 for chronic weight management in adults, has now been approved for chronic weight. (medletter.com)
  • The injectable glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Wegovy) , which was approved by the FDA in 2021 for chronic weight management in adults, has now been approved for chronic weight management in children ≥12 years old with an initial BMI in the ≥95th percentile for age and sex.Semaglutide is also available as Ozempic and Rybelsus for treatment of type 2 diabetes in adults. (medletter.com)
  • Tirzepatide, which is injected subcutaneously once weekly, is the first dual GIP/GLP-1 receptor agonist to become available in the US. (medletter.com)
  • The injectable glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide, previously approved by the FDA as Ozempic to treat type 2 diabetes and to reduce the risk of major adverse cardiovascular events. (medletter.com)
  • Liraglutide (Saxenda) , another subcutaneously injected GLP-1 receptor agonist, was approved for chronic weight management in 2015. (medletter.com)
  • In recently published clinical trials, once-weekly subcutaneous injection of the glucagon-like peptide 1 (GLP-1) receptor agonist semaglutide (Ozempic - Novo Nordisk), which is FDA-approved for treatment. (medletter.com)
  • Semaglutide is a glucagon-like peptide-1 receptor agonist. (wikipedia.org)
  • Their mechanisms of action range from working as a stimulant to being a glucagon-like peptide-1 (GLP-1) receptor agonist in order to suppress appetite and reduce caloric intake. (axxiem.com)
  • They called this 'glucose agonist' - later known as glucagon - for its ability to oppose the hypoglycaemic effect of insulin. (easd-elearning.org)
  • The pancreatic effects of the "twincretin" tirzepatide (Mounjaro) appear to depend at least as much on the drug's agonist activity on the glucose-dependent insulinotropic polypeptide (GIP) receptor as on its glucagon-like peptide-1 (GLP-1) receptor activity. (medscape.com)
  • The data show that tirzepatide stimulates islet hormone secretion from human islets through agonist effects at both incretin receptors (GIP and GLP-1). (medscape.com)
  • Disclosed herein are methods of treating allergic disorders and respiratory syncytial virus (RSV) infections with a glucagon-like peptide-1 receptor (GLP-1R) agonist. (justia.com)
  • In some aspects, disclosed herein is a method of treating or preventing an allergic disease in a subject who has, or is at risk of developing an allergic disease, comprising administering to the subject a therapeutically effective amount of a glucagon-like peptide-1 receptor (GLP-1Rt) agonist. (justia.com)
  • Exenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist (incretin mimetics). (genetobe.com)
  • Altimmune Inc.'s peptide-based glucagon-like peptide-1/glucagon dual receptor agonist pemvidutide hiccupped in a phase I study earlier this year but has bounced. (bioworld.com)
  • In two phase 3 studies, OASIS 1 and PIONEER PLUS, Vanita R. Aroda, M.D., of the Brigham and Women's Hospital and Harvard Medical School in Boston, and colleagues found that higher doses of orally administrated semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist (RA), results in significant weight loss and hemoglobin A1c (HbA1c) reductions. (healthday.com)
  • For OASIS 1, these results indicate that oral semaglutide 50 mg may provide an effective, future option for people with overweight or obesity who would benefit from a GLP-1 receptor agonist,' Aroda said. (healthday.com)
  • Biora is developing multiple molecules for delivery via the BioJet platform, including BT-002, a drug-device combination consisting of a variant of adalimumab delivered via the BioJet device for the treatment of inflammatory conditions, and BT-200, which consists of a GLP-1 receptor agonist delivered via the BioJet device for the treatment of type 2 diabetes. (healthtechnologynet.com)
  • The pharmacodynamics of ALT-801, a GLP-1/glucagon receptor dual agonist optimized for NASH and weight loss, were compared to semaglutide (GLP-1 receptor agonist) and elafibranor (peroxisome proliferator-activated receptor, PPAR-α/δ, agonist) in a biopsy-confirmed, diet-induced obese (DIO) mouse model of NASH (DIO-NASH). (researchsquare.com)
  • More recently the clinical use of GLP-1R agonist based therapeutics at high doses for the treatment of obesity and diabetes has resulted in weight loss in the 9-16% range over 26-68 weeks depending on diabetes status and the degree of lifestyle intervention 7,8 . (researchsquare.com)
  • Beyond the GLP-1 receptor (GLP-1R) agonists, unimolecular peptide dual agonists activating both GLP-1R and the glucagon receptor (GCGR) have been developed with the aim to achieve superior therapeutic benefits versus single agonist peptides 12 , 13 . (researchsquare.com)
  • GZR18 is a glucagon-like peptide-1 receptor agonist (GLP-1RA) with potential to treat patients with type 2 diabetes. (pipelinereview.com)
  • Dulaglutide: a novel once-weekly glucagon-like peptide-1 receptor agonist. (medscape.org)
  • Rendell MS. Albiglutide: a unique GLP-1 receptor agonist. (medscape.org)
  • It has a number of drug candidates in the pipeline targeting both pulmonary and metabolic conditions, but much of the interest is focused on GSBR-1290, an oral receptor agonist of glucagon-like-peptide-1, or GLP-1. (spynewstoday.com)
  • The drug is highly selective and is a potent agonist for peroxisome proliferator-activated receptor gamma (PPAR gamma). (medscape.com)
Secretion21
  • Stimulation of insulin secretion from pancreatic β-cells by glucagon-like peptide 1 receptor (GLP-1R) agonists is known to be glucose-dependent. (nih.gov)
  • After a mixed meal, glucagon secretion might increase in response to the protein and lipid content of the meal. (easd-elearning.org)
  • abstract = 'Incretins, enhancers of insulin secretion, are essential for glucose tolerance, and a reduction in their function might contribute to poor beta-cell function in patients with type-2 diabetes mellitus. (ku.dk)
  • However, at supraphysiological doses, the incretin glucagon-like peptide-1 (GLP-1) protects pancreatic beta cells, and inhibits glucagon secretion, gastric emptying and food intake, leading to weight loss. (ku.dk)
  • Glucagon-like peptide-1 (GLP-1) is an important endogenous incretin hormone, which stimulates glucose-dependent insulin secretion from the pancreatic islet cells and supports glucose homeostasis [ 7 ], as well as stimulating β -cell proliferation and inhibiting β -cell apoptosis, increasing insulin sensitivity, and inhibiting glucagon secretion and gastrointestinal motility [ 7 - 10 ]. (hindawi.com)
  • The researchers determined which incretin receptor (GLP-1 or GIP) tirzepatide uses to stimulate insulin secretion in isolated human pancreatic islet cells from donors. (medscape.com)
  • The investigators also determined which incretin receptor plays the major role in stimulating glucagon secretion from isolated human pancreatic islet cells. (medscape.com)
  • Antagonism of the GIP receptor consistently decreased tirzepatide-stimulated insulin secretion across all donor islet cell samples, while the impact of GLP-1 receptor antagonism varied among islet preparations. (medscape.com)
  • In isolated human islets, the researchers confirmed that human GIP stimulated glucagon secretion, human GLP-1 decreased glucagon secretion, and the combination of the two was offsetting to produce a rate of glucagon secretion that matched unstimulated levels. (medscape.com)
  • GIP receptor agonism appears important for inducing both insulin and glucagon secretion from isolated human pancreatic islet cells. (medscape.com)
  • The data clearly demonstrate that in isolated human islets, tirzepatide requires the GIP receptor to stimulate both insulin and glucagon secretion," the authors conclude . (medscape.com)
  • GLP-1 has a role in glycemic control by inducing glucose-dependent insulin secretion from β-cells and inhibiting glucagon release from α-cells in the pancreas. (justia.com)
  • Regarding Type 1 diabetes(T1D), animal/islet-cell studies found that GABA promotes insulin secretion, inhibits α-cell glucagon and dampens immune inflammation, while GAD immunization may also preserve β-cells. (nature.com)
  • In vitro experiments found that isolated human islets treated with GABA receptor blockade have decreased insulin secretion at physiologic glucose concentrations 18 . (nature.com)
  • Further, GABA-deficient islets did not show appropriate glucagon inhibition in response to increasing glucose concentrations in vitro 22 , suggesting that GABA is directly involved in the suppression of glucagon secretion in pancreatic alpha cells. (nature.com)
  • Glucagon-like peptide-1 (GLP-1) is an incretin hormone responsible for many glucoregulatory effects such as the stimulation of insulin secretion and the inhibition of glucagon when blood glucose is high 2 . (pipelinereview.com)
  • My research focus is to understand how we can circumvent the reduced capacity of the pancreatic beta cells to secrete enough insulin, and why the control of alpha cell glucagon secretion becomes disturbed in diabetes. (lu.se)
  • Others and we suggest that the beta cell release primed insulin granules during first phase insulin secretion, which is lacking in individuals with pre-diabetes. (lu.se)
  • We are currently performing functional investigations of key miRNAs and their role in insulin- and/or glucagon secretion. (lu.se)
  • In the future, we will use this knowledge in the attempt to rescue the diabetic phenotype using LNA antagomirs as possible therapeutics to influence insulin and glucagon secretion. (lu.se)
  • Altogether, our studies aim to increase the understanding of insulin- and glucagon secretion in the complex disease diabetes. (lu.se)
Agonists12
  • GLP-1 receptor agonists have been available for years. (medletter.com)
  • The glucagon-like peptide-1 receptor agonists (GLP-1RAs) were recommended as a monotherapy or combination therapy with oral hypoglycemic agents or basal insulin in the position statement of the Korean Diabetes Association 2017 for pharmacological therapy. (e-dmj.org)
  • Glucagon-like peptide-1 receptor agonists, such as Exendin-4, have emerged as potential treatments for type 2 diabetes and obesity. (bvsalud.org)
  • Based on product type, the market for treatments for metabolic disorders has been divided into insulin, oral diabetes medications, GLP-1 receptor agonists, DPP-4 inhibitors, and others. (reportsanddata.com)
  • The present disclosure relates to glucagon-like peptide-1 receptor (GLP-1R) agonists and methods of treating or preventing allergic inflammation and/or methods of treating or preventing respiratory syncytial virus (RSV) infection. (justia.com)
  • GLP-1 receptor (GLP-1R) agonists, such as liraglutide and exenatide are approved by the Food and Drug Administration (FDA) for treatment of type 2 diabetes (T2D). (justia.com)
  • GLP-1R agonists (also known as incretin mimetics or GLP-1 analogs) are a class of drugs used to treat Type 2 diabetes and obesity. (discoverx.com)
  • What the reader will gain: Long-acting GIP receptor agonists offer a potential new class of antidiabetic drugs. (ulster.ac.uk)
  • At their essence, they are agonists of the GLP-1 receptor. (bmidoctors.com)
  • GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. (pipelinereview.com)
  • 3. Brunton SA, Wysham CH. GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date. (pipelinereview.com)
  • The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. (medscape.org)
Incretin9
  • By mimicking the action of the incretin glucagon-like peptide-1 (GLP-1), it increases the production of insulin, the hormone that lowers the blood sugar level. (wikipedia.org)
  • Incretin hormone includes glucagon-like peptide-1 (GLP-1) from L-cells and glucose-dependent insulinotrophic polypeptide from K-cells of the small intestine. (e-dmj.org)
  • Effects of Incretin-based Therapies on Weight-related Indicators among Patients with Type 2 Diabetes: A Network Meta-analysis. (mcmaster.ca)
  • GLP-1 mimetics, which are stable-peptide-based activators of the GLP-1 receptor, and incretin enhancers, which inhibit the incretin-degrading enzyme dipeptidyl peptidase-4, have emerged as therapies for type-2 diabetes and have recently reached the market. (ku.dk)
  • The gut-derived incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) are known for insulinotropic and glucose-lowering effects. (diabetesjournals.org)
  • More recent incretin-based treatment strategies include glucagon-like peptide-1 (GLP-1) mimetics and inhibitors of the enzyme that degrades GLP-1, dipeptidyl peptidase-4 (DPP-4). (ddw-online.com)
  • Therapeutic potential of the original incretin hormone glucose-dependent insulinotropic polypeptide: diabetes, obesity, osteoporosis and Alzheimer's disease? (ulster.ac.uk)
  • To date, the physiological importance of GIP has received much less attention than its younger sister incretin hormone glucagon-like peptide-1. (ulster.ac.uk)
  • Dive into the research topics of 'Therapeutic potential of the original incretin hormone glucose-dependent insulinotropic polypeptide: diabetes, obesity, osteoporosis and Alzheimer's disease? (ulster.ac.uk)
Mellitus15
Blood glucose6
  • This may explain why a recent study of people with type 1 diabetes treated with a glucagon receptor (GCGR) antagonist showed little effect of this potential therapy on blood glucose levels. (easd-elearning.org)
  • Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). (medscape.org)
  • Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. (medscape.org)
  • Activation of PPAR-gamma receptors regulates insulin-responsive gene transcription involved in glucose production, transport, and utilization, thereby reducing blood glucose concentrations and reducing hyperinsulinemia. (medscape.com)
  • Type 2 diabetes (T2D) is the major form of diabetes and obesity and physical inactivity influence the disease development leading to the elevated blood glucose level. (lu.se)
  • The main hormone regulating the blood glucose levels is insulin, secreted from beta cells, and glucagon, secreted from alpha cells. (lu.se)
Production of glucagon2
Therapeutic8
  • Advanced microbiome therapeutics (AMTs) holds promise in utilizing engineered microbes such as bacteria or yeasts for innovative therapeutic applications, including the in situ delivery of therapeutic peptides. (bvsalud.org)
  • In this review, Nicolai Albrechtsen of Copenhagen University Hospital and colleagues elsewhere took a detailed look at what we now know about glucagon, including its role in diabetes and promise as a therapeutic. (easd-elearning.org)
  • The launch of Zucara Therapeutics is an excellent example of how many partners can work together, leveraging complementary strengths, and sharing risk and reward to translate and commercialize an innovative and much-needed therapeutic," says Karimah Es Sabar , president and CEO of CDRD. (tiap.ca)
  • Offering a novel approach to the management of chronic conditions, especially Type 2 diabetes and obesity, GLP-1 medications herald a transformative era, redefining the paradigms of therapeutic intervention. (bmidoctors.com)
  • Biora Therapeutics is the biotech company that is reimagining therapeutic delivery. (healthtechnologynet.com)
  • This trial demonstrates Gan & Lee's long-term commitment to strengthening our pipeline in diabetes and other therapeutic areas to benefit the patient and medical community" said Dr. Mike Hu, the Chief Executive Officer (CEO) & President of Gan & Lee Pharmaceuticals USA Corporation. (pipelinereview.com)
  • Scheen AJ, Van Gaal L. Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. (medscape.org)
  • Bhavsar S, Mudaliar S, Cherrington A. Evolution of exenatide as a diabetes therapeutic. (medscape.org)
Inhibits glucagon1
  • GLP-1 stimulates glucose-dependent insulin release, inhibits glucagon release, delays gastric emptying, and suppresses the appetite through GLP-1 receptor binding. (e-dmj.org)
Gastric2
  • Meanwhile, Christian de Duve, Earl Sutherland and colleagues identified the secretory origin of glucagon as the pancreatic alpha cells and discovered that the gastric mucosa are another source of glucagon. (easd-elearning.org)
  • Perhaps the most infamous is the combination drug Roux-en-Y gastric bypass, biliopancreatic diversion with duo- Fen-Phen. (eddoctor24h.com)
Pharmacology1
  • advance online publication 13 Nov CliniCal PHarMaCOlOGy & THeraPeuTiCs VOLUME 95 NUMBER 1 JANUARy 2014 state art however, the overall rates of overweight adults and children SAFETY ISSUES WITH WEIGHT-LOSS DRUGS remain stubbornly large.7 Drugs can be very effective in inducing weight loss. (eddoctor24h.com)
Semaglutide5
  • An oral formulation of semaglutide (Rybelsus) has been available since 2019 for treatment of type 2 diabetes, but it is not approved for weight management. (medletter.com)
  • Semaglutide, sold under the brand names Ozempic, Wegovy and Rybelsus, is an antidiabetic medication used for the treatment of type 2 diabetes and an anti-obesity medication used for long-term weight management. (wikipedia.org)
  • Semaglutide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. (wikipedia.org)
  • In 2012, a team of researchers at Novo Nordisk developed semaglutide for a once-weekly diabetes therapy as a longer-acting alternative to liraglutide. (wikipedia.org)
  • The PIONEER PLUS trial compared doses of oral semaglutide higher than currently approved (25 and 50 mg daily versus currently approved 14 mg daily), demonstrating significantly superior HbA1c reduction and body weight reduction at both of the higher doses compared with 14 mg in adults with type 2 diabetes. (healthday.com)
Hormone6
  • The FDA has approved tirzepatide (Mounjaro - Lilly), a peptide hormone with activity at both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, to improve. (medletter.com)
  • It is a peptide similar to the hormone glucagon-like peptide-1 (GLP-1), modified with a side chain. (wikipedia.org)
  • While the recent 100th anniversary of the discovery of insulin was widely acknowledged in the diabetes community, much less attention has been paid to the centenary of its vital counter-regulatory hormone, glucagon. (easd-elearning.org)
  • Glucagon-like peptide-1 (GLP-1) is a peptide hormone synthesized and released by enteroendocrine L-cells in the ileum and large intestine following oral food intake. (justia.com)
  • By simulating the GLP-1 hormone, these drugs harness its benefits and augment them, crafting a potent strategy to combat diabetes and obesity. (bmidoctors.com)
  • Congenital causes include abnormalities of the GH-releasing hormone receptor and of the GH1 gene and certain central nervous system (CNS) malformations. (msdmanuals.com)
Clinical6
  • To redress the balance, a new review in Diabetologia looks at the biology and clinical aspects of glucagon, and at the promise of glucagon-based therapies. (easd-elearning.org)
  • The pathophysiological basis the clinical use of these therapeutics is reviewed here. (ku.dk)
  • In this latest transaction, Intarcia further retains control of its lead product candidate ITCA 650 - its novel once-yearly GLP-1 for type two diabetes, currently being investigated in a global phase 3 clinical trial program called FREEDOM. (nlvpartners.com)
  • I'm Dr. Anne Peters, Director of the Clinical Diabetes Program at the University of Southern California. (medscape.com)
  • I am joined today by Dr. Julio Rosenstock, Director, Dallas Diabetes and Endocrine Center and Clinical Professor of Medicine, University of Texas Southwestern Medical Center. (medscape.com)
  • Julio, we were working on the clinical therapeutics committee together. (medscape.com)
Structure Therapeutics2
Exenatide1
  • Exenatide shows 53% sequence homology with native GLP-1, while still binding effectively to GLP-1 receptor on pancreatic β cells for its insulinotropic effects. (hindawi.com)
Cardiovascular7
  • Also, as obesity is a significant risk factor for developing metabolic illnesses such as diabetes and cardiovascular diseases, it is boosting market revenue growth. (reportsanddata.com)
  • As a physician-scientist, Dr. Chen has made seminal contributions to advance the field of cardiovascular biology and diabetes treatment. (genetobe.com)
  • Diabetes has long been recognized as a major contributor to the development of cardiovascular disease. (broadviewventures.org)
  • Moreover, the mere control of blood sugar doesn't address the multifactorial complications of diabetes, which often include cardiovascular risks. (bmidoctors.com)
  • Moving forward to advance our goal of becoming a world-class pharmaceutical company, we will also take an active part in developing new chemical entities, and work on the treatment of cardiovascular diseases, metabolic diseases, cancer, and other therapeutics. (pipelinereview.com)
  • Epidemiology of obesity and diabetes and their cardiovascular complications. (medscape.org)
  • Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. (medscape.org)
Peptides1
Therapies1
  • Currently, no preventative therapy for hypoglycemia exists, leaving patients to rely on rescue therapies, such as glucose or glucagon, which can only be used after the patient is already suffering from a potentially dangerous hypoglycemic episode. (tiap.ca)
T2DM5
  • The increasing global prevalence of T2DM and obesity has advanced the discovery and development of novel therapeutics targeting T2DM and obesity. (discoverx.com)
  • In recent years, the focus on therapeutics for T2DM has shifted towards the development of not only glucose-lowering drugs, but also those that can reduce body weight. (discoverx.com)
  • This altered glucose metabolism state is associated with an increased risk of developing T2DM (Figure 1), although other parameters including excess adiposity, inflammation and dyslipidemia are risk factors associated with the development of insulin resistance, loss of pancreatic function, worsening of hyperglycemia and progression to diabetes (1). (ddw-online.com)
  • Despite beneficial effects of current glucose-lowering treatments, disease-related morbidity and mortality remain considerable in T2DM patients, galvanising the search for innovative medications that target the multiple metabolic abnormalities as well as inflammatory processes and other pathways predisposing to diabetes-associated disorders. (ddw-online.com)
  • New therapeutics must therefore address the multi-factorial nature of T2DM, and aim to treat diabetic patients at an earlier stage of the disease, if pharmacological interventions hope to halt the epidemic. (ddw-online.com)
Antagonist1
  • We infused the GIP receptor antagonist GIP(3-30)NH 2 and the GLP-1 receptor antagonist exendin(9-39) during a meal to determine the roles of endogenous GIP and GLP-1 on postprandial glucose metabolism. (diabetesjournals.org)
Exocrine pancreas1
  • Our work on improving imaging in type 1 diabetes through blocking exocrine pancreas receptors has been published in the Journal of Nuclear Medicine. (umich.edu)
Pancreas4
NASDAQ1
  • TORONTO, June 30, 2016 - Cynapsus Therapeutics Inc. (NASDAQ:CYNA) (TSX:CTH), a specialty central nervous system (CNS) pharmaceutical company developing and preparing to commercialize APL-130277, a fast-acting, easy-to-use, sublingual thin film for the on-demand management of debilitating OFF episodes associated with Parkinson's disease (PD), announced today that the last patient has been enrolled in its pivotal Phase 3 efficacy study, CTH-300. (traderpower.com)
20162
  • TORONTO and VANCOUVER, CANADA (January 12, 2016) - A novel drug therapy to reduce the severity and frequency of hypoglycemic (low blood sugar) episodes in people with diabetes is being developed by Zucara Therapeutics Inc . (tiap.ca)
  • Zucara Therapeutics will attend Does of the Valley in February 2016. (tiap.ca)
Liraglutide1
  • Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. (medscape.org)
Analogs5
  • Since insulin therapy is regarded as the gold standard for controlling diabetes, creating new insulin products, such as long-acting insulin analogs, is expected to increase this market's revenue. (reportsanddata.com)
  • While the use of glucagon-like peptide1 (GLP-1) analogs in the control of diabetes has been associated with appetite suppression and reduced food intake, substantial numbers of patients exhibit gastrointestinal side effects (nausea, emesis) and average weight loss has ranged from 1-7% in studies leading to approval 6 . (researchsquare.com)
  • We have a lot of data on the glucagon -like polypeptide-1 (GLP-1) receptor analogs that are available. (medscape.com)
  • In combination with insulin, the GLP-1 analogs are another new way of treating type 2 diabetes. (medscape.com)
  • The data showing that the combination of GLP-1 receptor analogs and basal insulin works very well are interesting. (medscape.com)
Human islets1
  • However, they add: "It is important to note that although the human islets we utilized came from donors with a broad range of metabolic characteristics, we did not have the opportunity to include islets from donors with type 2 diabetes . (medscape.com)
Prevalence of type 2 diabet2
  • The market for oral antidiabetic medications is expanding due to the rising prevalence of type 2 diabetes, particularly in emerging economies. (reportsanddata.com)
  • The prevalence of Type 2 diabetes has skyrocketed, painting a grim picture of global health. (bmidoctors.com)
Pathways1
Translational1
  • Additionally, Dr. Chen is the Founding Director of the Center for Advanced Models for Translational Sciences and Therapeutics at UM since July 2012, which generates gene-targeted (knockout and knockin) and transgenic rabbits/pigs for human disease models. (genetobe.com)
Potent1
  • Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. (medscape.org)
Islets1
  • Since then my research group have performed detailed analysis of miRNAs in beta-cell function by investigations of islets from different diabetes animal models, and from human donors. (lu.se)
Metabolic disorder2
  • The global Metabolic Disorder Therapeutics Market size was USD 130.81 billion in 2022, and is expected to reach a value of USD 240.49 billion in 2032, and register a revenue CAGR of 7% during the forecast period. (reportsanddata.com)
  • The metabolic disorder therapeutics market's rise in the insulin sector is primarily driven by the rising prevalence of diabetes globally. (reportsanddata.com)
Glycemic control2
  • Diet, exercise, and weight loss can improve glycemic control, but almost all patients with type 2 diabetes require antihyperglycemic drug therapy. (medletter.com)
  • There were no clinically significant differences in glycemic control or diabetes antibody titers. (nature.com)
People with type 2 diabet1
  • Heart disease and stroke are the major causes of death and disability among people with Type 2 diabetes. (broadviewventures.org)
Treatment of type 2 diabet1
  • Take home message: GIP-based therapeutics have potential for the treatment of type 2 diabetes and obesity, with the possibility of further beneficial actions in osteoporosis and cognitive decline. (ulster.ac.uk)
Suppression1
Homeostasis1
Gestational1
  • It is used to treat type 1 and type 2 diabetes and gestational diabetes. (reportsanddata.com)
Type 2 diabetes and obesi1
  • The US Food and Drug Administration (FDA) has established regulations to approve drugs for metabolic disorders, including type 2 diabetes and obesity. (reportsanddata.com)
Regulates1
Vitro1
  • Study protocols ran in vitro on such cells from human donors who did not have diabetes and who had a broad range of metabolic characteristics. (medscape.com)
Treat type 2 diabet2
  • In reducing blood sugar levels, oral antidiabetic medicines treat type 2 diabetes. (reportsanddata.com)
  • Eli Lilly's Mounjaro is approved to treat type 2 diabetes and Lilly expects to gain clearance for obesity treatment later this year. (spynewstoday.com)
Glucose control4
  • Researchers have revealed that treatment with recombinant growth differentiating factor 15 (GDF15) reduces obesity and improves glucose control by suppressing food intake via glial-cell-derived neurotrophic factor family receptor α-like (GFRAL). (axxiem.com)
  • Intarcia has created a remarkably promising diabetes product with the potential to simplify glucose control and be a cost-effective solution with ensured compliance built-in, which would be inconceivable by any other means. (nlvpartners.com)
  • Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. (medscape.org)
  • Glucose control and vascular complications in veterans with type 2 diabetes. (medscape.org)
International Diabetes F3
  • According to the International Diabetes Federation (IDF), around 463 million persons were living with diabetes in 2019, which is expected to climb to 700 million by 2045. (reportsanddata.com)
  • According to the International Diabetes Federation, more than 285 million people (6.4% of the world population) are currently estimated to suffer from diabetes, a figure which is expected to rise to 438 million (7.8%) by 2030. (ddw-online.com)
  • 1. International Diabetes Federation. (pipelinereview.com)
Concentrations2
  • And with the introduction of the first glucagon radioimmunoassay by Roger Unger and colleagues in 1959, it became possible to measure plasma concentrations of glucagon and therefore study its physiology and role in pathophysiological processes. (easd-elearning.org)
  • This led to the discovery that people with diabetes have increased plasma glucagon concentrations. (easd-elearning.org)
Pancreatic cells1
  • Dr. Mladen Vranic (Banting and Best Diabetes Center and professor emeritus in the Faculty of Medicine at U of T) and his research team developed compelling evidence that pancreatic cells, which regulate hypoglycemia by secreting glucagon, are impaired in diabetes by high somatostatin levels. (tiap.ca)
Newly diagnosed1
  • Meanwhile, hyperglucagonaemia has also been reported in people newly diagnosed with type 1 diabetes and in animal models. (easd-elearning.org)
Lilly1
  • The study's lead researchers were based at Duke University in Durham, North Carolina, the German Center for Diabetes Research in Neuherberg, Germany, and at Eli Lilly, the company that markets tirzepatide (Mounjaro). (medscape.com)
Obese3
  • Independent of its weight loss effect, metabolic surgery substantially improves or even resolves diabetes within days in 80 to 90 percent of obese Type 2 diabetes patients. (broadviewventures.org)
  • This surgery is equally effective in non-obese diabetes patients. (broadviewventures.org)
  • Interestingly, an analysis by pharmacy benefits manager Prime Therapeutics of obese patients (not with T2D) found that only 32% of those observed who started taking GLP-1 RAs (half Ozempic/Wegovy, the rest a mix of Saxenda or Rybelsus) were still taking the drugs 12 months later despite all participants having insurance coverage," he said. (nordynenewscenter.com)
Systemic2
  • Biora's BioJet systemic oral therapeutics platform uses an ingestible capsule for needle-free, oral delivery of large molecules designed to achieve systemic bioavailability and replace injection for better management of chronic diseases. (healthtechnologynet.com)
  • Biora is focused on development of two therapeutics platforms: the NaviCap™ targeted oral delivery platform , which is designed to improve outcomes for patients with inflammatory bowel disease through treatment at the site of disease in the gastrointestinal tract, and the BioJet™ systemic oral delivery platform , which is designed to replace injection for better management of chronic diseases through needle-free, oral delivery of large molecules. (healthtechnologynet.com)
Protein2
  • Glucagon-Like Peptide-1 (GLP-1), a member of the glucagon-secretin peptide family, is secreted from L-cells of the small intestine and binds to GLP-1 receptor (GLP-1R), a class B G Protein-Coupled Receptor (GPCR). (discoverx.com)
  • The company's stock symbol, GPCR, is a nod to its focus on G protein-coupled receptors, which help cells function. (spynewstoday.com)
Patients9
  • The world's economy coughs out billions of dollars annually to diagnose, treat and manage patients with diabetes. (openmedicinalchemistryjournal.com)
  • We expect this product to be welcomed by patients, physicians, and importantly payors who desperately need new ways to overcome the huge financial burden associated with diabetes," said Peter Kolchinsky, Managing Director of RA Capital, and one of the key new investors in Intarcia. (nlvpartners.com)
  • There is much more to be done but our interim phase 3 data in type two diabetes is an exciting glimpse at the potential we have to make a real difference for many patients, payors and providers alike," added Graves. (nlvpartners.com)
  • This new therapy has the potential to eliminate the fear of hypoglycemia in patients with diabetes," said Riddell, professor, School of Kinesiology and Health Science, Faculty of Health, York University. (tiap.ca)
  • Two-thirds of the patients in the study had diabetes. (healthday.com)
  • Many of these glucoregulatory effects are often impaired in patients with type 2 diabetes 3 . (pipelinereview.com)
  • In most cases, the diagnosis of a type of diabetes or glucose intolerance is based on the patient's condition at the time, but not all patients have a set of symptoms that fit readily into a particular class (see Presentation ). (medscape.com)
  • The overall goal of my research has always been to increase the knowledge regarding alpha- and beta-cell function for the possible development of better treatment for patients with diabetes. (lu.se)
  • This is of interest since patients with cystic fibrosis (CF) today often develop CF-related Diabetes (CFRD). (lu.se)